Human gene therapy vectors derived from feline lentiviruses

Barraza, Román; Poeschla, Eric M.

doi:10.1016/j.vetimm.2008.01.009

Cited by 25 publications

(17 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…pNL4-3.Luc.R + E - was obtained from the National institutes of health AIDS reference and reagents program. Plasmids encoding HIV-1 Gag-Pol (pMDLg/pRRE; from Addgene), HIV-1 REV (pRSV-REV; from Addgene), NB-MLV Gag-Pol (CS2-mGP) [58], and FIV Gag-Pol (pFP93)[59]. …”

Section: Methodsmentioning

confidence: 99%

Non-human Primate Schlafen11 Inhibits Production of Both Host and Viral Proteins

Stabell

Hawkins

et al. 2016

PLoS Pathog

View full text Add to dashboard Cite

Schlafen11 (encoded by the SLFN11 gene) has been shown to inhibit the accumulation of HIV-1 proteins. We show that the SLFN11 gene is under positive selection in simian primates and is species-specific in its activity against HIV-1. The activity of human Schlafen11 is relatively weak compared to that of some other primate versions of this protein, with the versions encoded by chimpanzee, orangutan, gibbon, and marmoset being particularly potent inhibitors of HIV-1 protein production. Interestingly, we find that Schlafen11 is functional in the absence of infection and reduces protein production from certain non-viral (GFP) and even host (Vinculin and GAPDH) transcripts. This suggests that Schlafen11 may just generally block protein production from non-codon optimized transcripts. Because Schlafen11 is an interferon-stimulated gene with a broad ability to inhibit protein production from many host and viral transcripts, its role may be to create a general antiviral state in the cell. Interestingly, the strong inhibitors such as marmoset Schlafen11 consistently block protein production better than weak primate Schlafen11 proteins, regardless of the virus or host target being analyzed. Further, we show that the residues to which species-specific differences in Schlafen11 potency map are distinct from residues that have been targeted by positive selection. We speculate that the positive selection of SLFN11 could have been driven by a number of different factors, including interaction with one or more viral antagonists that have yet to be identified.

show abstract

Section: Methodsmentioning

confidence: 99%

Non-human Primate Schlafen11 Inhibits Production of Both Host and Viral Proteins

Stabell

Hawkins

et al. 2016

PLoS Pathog

View full text Add to dashboard Cite

show abstract

“…The EGFP-expressing prototype foamy virus (PFV) construct, pczDWP001, and the plasmid encoding PFV Env, pczHFVenvEM02, were described previously [36,37]. The reporter virus plasmids for FIV (pFP93 and pGINSIN) [38,39], EIAV (pONY3.2), RSV (pAlpha.SF.EGFP.WPRE and pcDNA.alpha.gag/pol.CO) [40], and MPMV (pSARM-EGFP) [41,42] have been previously described. pEIAV-RFP was a kind gift of Taichiro Takemura and Vineet KewalRamani and was derived from p6.1G3CeGFPW [43].…”

Section: Methodsmentioning

confidence: 99%

Restriction of diverse retroviruses by SAMHD1

et al. 2013

View full text Add to dashboard Cite

BackgroundSAMHD1 is a triphosphohydrolase that restricts the replication of HIV-1 and SIV in myeloid cells. In macrophages and dendritic cells, SAMHD1 restricts virus replication by diminishing the deoxynucleotide triphosphate pool to a level below that which supports lentiviral reverse transcription. HIV-2 and related SIVs encode the accessory protein Vpx to induce the proteasomal degradation of SAMHD1 following virus entry. While SAMHD1 has been shown to restrict HIV-1 and SIV, the breadth of its restriction is not known and whether other viruses have a means to counteract the restriction has not been determined.ResultsWe show that SAMHD1 restricts a wide array of divergent retroviruses, including the alpha, beta and gamma classes. Murine leukemia virus was restricted by SAMHD1 in macrophages yet removal of SAMHD1 did not alleviate the block to infection because of an additional block to viral nuclear import. Prototype foamy virus (PFV) and Human T cell leukemia virus type I (HTLV-1) were the only retroviruses tested that were not restricted by SAMHD1. PFV reverse transcribes predominantly prior to entry and thus is unaffected by the dNTP level in the target cell. It is possible that HTLV-1 has a mechanism to render the virus resistant to SAMHD1-mediated restriction.ConclusionThe results suggest that SAMHD1 has broad anti-retroviral activity against which most viruses have not found an escape.

show abstract

“…Lentiviral vectors are easy to engineer to infect a wide variety of cell types, depending on the envelope used to produce the recombinant virus, and transduce cells regardless of the replication status, in vitro and in vivo, ultimately resulting in integration into the genome of the host cell. Lentiviral vectors have been developed from primate lentiviruses, including those based on HIV-1 and HIV-2 [10,11], simian immunodeficiency virus (SIV) [12] and non primate lentiviruses, including those based on feline immunodeficiency virus (FIV) [13], bovine immunodeficiency virus (BIV) [14], equine infectious anemia virus (EIAV) [15], caprine arthritis encephalitis virus (CAEV) [16], Jembrana disease virus (JDV) [17] and visna virus (VV) [18]. Among lentiviral vectors, those based on HIV-1 and SIV, due to the pathogenic consequences of the parental virus, have been studied the most.…”

Section: Lentiviral Vectors: Development Characteristics and Activitiesmentioning

confidence: 99%

Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity

Negri

Michelini

Bona

et al. 2011

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

IDLV are a recent acquisition in the field of genetic immunization, thus allowing for the opportunity of further upgrading, including increasing antigen expression and potency of immune response. Based on recent reports showing the potential of IDLV for immunization in mouse models, further development and validation of IDLV, including comparison with other vaccine protocols and use in non-human primate models, are warranted.

show abstract

Human gene therapy vectors derived from feline lentiviruses

Cited by 25 publications

References 81 publications

Non-human Primate Schlafen11 Inhibits Production of Both Host and Viral Proteins

Non-human Primate Schlafen11 Inhibits Production of Both Host and Viral Proteins

Restriction of diverse retroviruses by SAMHD1

Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity

Contact Info

Product

Resources

About